사일런스 테라퓨틱스(SLN)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $12.20 (-3.94%), 시가총액 $0.29B, 52주 최저~최고 $4.30 ~ $7.97.
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc
사일런스 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
사일런스 테라퓨틱스의 현재 주가는 $12.20 (-3.94%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
사일런스 테라퓨틱스의 시가총액은 약 $0.29B입니다.
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of spe